Trial · NCT01621776
Effect of Apidra Compared to Humalog in Decreasing Post-Prandial Hyperglycemia
NCT01621776, Not applicable, Completed, University of Florida; results first posted 2013-09-13
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Effect of Apidra Compared to Humalog in Decreasing Post-Prandial Hyperglycemia. Trials, record NCT01621776. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01621776
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Effect of Apidra Compared to Humalog in Decreasing Post-Prandial Hyperglycemia
- NCT number
- NCT01621776
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 107 participants, actual
- Lead sponsor
- University of Florida
- Conditions
- Type 1 Diabetes
- Interventions
- Apidra, Humalog, Novolog
- First posted
- 2012-06-18
- Last updated
- 2013-09-13
- Results first posted
- 2013-09-13
- Limitations and caveats
In the first year (Camp 2011) there were 2 arms, the Humalog and Apidra. In the second year (Camp 2012) there were 3 arms, the Humalog, Apidra, and Novolog. Therefore, there will be more participants in the Humalog and Apidra arms.
Source ClinicalTrials.gov
Registered outcomes3
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | The Difference Between Pre- and 120 Minute Post-prandial Blood Glucose Concentrations at Lunch. | averaged over 5 days | Blood glucose concentrations were measured prior to and 90 minutes following lunch. Analysis was based on intention to treat. While missing data was imputed, it was known that this data was 'not missing at random' thus violating standard statistical assumptions with imputation. Therefore imputed data was not included in the final model. The number of participants for analysis was based upon a convenience sample of individuals attending Florida Camp for Children and Youth with Diabetes at Camp Winona. |
| Secondary | Difference Between Pre- and 120 Minute Post-prandial Blood Glucose Concentrations at Dinner | averaged over 5 days | Blood glucose concentrations were measured prior to and 120 minutes following dinner. Analysis was based on intention to treat. While missing data was imputed, it was known that this data was 'not missing at random' thus violating standard statistical assumptions with imputation. Therefore imputed data was not included in the final model. |
| Secondary | Difference Between Pre- and 120 Minute Post-prandial Blood Glucose Concentrations at Breakfast | averaged over 5 days | Blood glucose concentrations were measured prior to and 120 minutes following breakfast. Analysis was based on intention to treat. While missing data was imputed, it was known that this data was 'not missing at random' thus violating standard statistical assumptions with imputation. Therefore imputed data was not included in the final model. |
Source ClinicalTrials.gov
Outcomes3
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | The Difference Between Pre- and 120 Minute Post-prandial Blood Glucose Concentrations at Lunch. | averaged over 5 days | Post-Prandial Blood Glucose Values \[Within 90 minutes following the completion of participant lunch\] | mg/dl | MEAN |
| SECONDARY | Difference Between Pre- and 120 Minute Post-prandial Blood Glucose Concentrations at Dinner | averaged over 5 days | mg/dl | MEAN | |
| SECONDARY | Difference Between Pre- and 120 Minute Post-prandial Blood Glucose Concentrations at Breakfast | averaged over 5 days | mg/dl | MEAN |
Source ClinicalTrials.gov
Results by group9
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| The Difference Between Pre- and 120 Minute Post-prandial Blood Glucose Concentrations at Lunch. | Humalog | 146.69 | Standard Deviation 79.19 | mg/dl | |
| The Difference Between Pre- and 120 Minute Post-prandial Blood Glucose Concentrations at Lunch. | Apidra | 143.68 | Standard Deviation 79.48 | mg/dl | |
| The Difference Between Pre- and 120 Minute Post-prandial Blood Glucose Concentrations at Lunch. | Novolog | 149.02 | Standard Deviation 71.56 | mg/dl | |
| Difference Between Pre- and 120 Minute Post-prandial Blood Glucose Concentrations at Dinner | Humalog | 170.57 | Standard Deviation 50.54 | mg/dl | |
| Difference Between Pre- and 120 Minute Post-prandial Blood Glucose Concentrations at Dinner | Apidra | 160.96 | Standard Deviation 73.54 | mg/dl | |
| Difference Between Pre- and 120 Minute Post-prandial Blood Glucose Concentrations at Dinner | Novolog | 153.46 | Standard Deviation 62.72 | mg/dl | |
| Difference Between Pre- and 120 Minute Post-prandial Blood Glucose Concentrations at Breakfast | Humalog | 225.62 | Standard Deviation 111.48 | mg/dl | |
| Difference Between Pre- and 120 Minute Post-prandial Blood Glucose Concentrations at Breakfast | Apidra | 225.46 | Standard Deviation 81.14 | mg/dl | |
| Difference Between Pre- and 120 Minute Post-prandial Blood Glucose Concentrations at Breakfast | Novolog | 208.64 | Standard Deviation 76.53 | mg/dl |
Source ClinicalTrials.gov
Participant flow9
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Humalog | 41 | |
| Overall Study | STARTED | Apidra | 40 | |
| Overall Study | STARTED | Novolog | 18 | |
| Overall Study | COMPLETED | Humalog | 41 | |
| Overall Study | COMPLETED | Apidra | 40 | |
| Overall Study | COMPLETED | Novolog | 18 | |
| Overall Study | NOT COMPLETED | Humalog | 0 | |
| Overall Study | NOT COMPLETED | Apidra | 0 | |
| Overall Study | NOT COMPLETED | Novolog | 0 |
Source ClinicalTrials.gov
Adverse events3
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Hypoglycemic Event | Endocrine disorders | Humalog | 41 | 41 | 105 |
| other | Hypoglycemic Event | Endocrine disorders | Apidra | 40 | 40 | 124 |
| other | Hypoglycemic Event | Endocrine disorders | Novolog | 18 | 18 | 35 |
Source ClinicalTrials.gov
Adverse event totals9
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Humalog | ||
| Total, all-cause mortality | Apidra | ||
| Total, all-cause mortality | Novolog | ||
| Total, other adverse events | Humalog | 41 | 41 |
| Total, other adverse events | Apidra | 40 | 40 |
| Total, other adverse events | Novolog | 18 | 18 |
| Total, serious adverse events | Humalog | 0 | 41 |
| Total, serious adverse events | Apidra | 0 | 40 |
| Total, serious adverse events | Novolog | 0 | 18 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01621776
GET https://conductscience.org/api/trials/v1/NCT01621776/registered